ArticleNeuro-oncology2018
Early posttreatment assessment of MRI perfusion biomarkers can predict long-term response of lung cancer brain metastases to stereotactic radiosurgery.
Article in Neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- A systematic review of brain metastases from lung cancer using magnetic resonance neuroimaging: Clinical and technical aspects.Journal of medical radiation sciences · 2024Pooled it
- Detectability of radiation-induced changes in magnetic resonance biomarkers following stereotactic radiosurgery: A pilot study.PloS one · 2018Trial
- Predictive value of early DCE and DSC perfusion MRI parameters for midterm clinical outcomes in lung cancer brain metastases treated with stereotactic radiosurgery.Journal of neuro-oncology · 2025Article
- Prediction of radiologic outcome-optimized dose plans and post-treatment magnetic resonance images: A proof-of-concept study in breast cancer brain metastases treated with stereotactic radiosurgery.Physics and imaging in radiation oncology · 2024Article
- Radiosurgery-induced early changes in peritumoral tissue sodium concentration of brain metastases.PloS one · 2024Article
- Radiosurgery for Brain Metastases: Challenges in Imaging Interpretation after Treatment.Cancers · 2023Review
- The emerging potential of quantitative MRI biomarkers for the early prediction of brain metastasis response after stereotactic radiosurgery: a scoping review.Quantitative imaging in medicine and surgery · 2023Article
- A prospective study assessing the pattern of response of local disease at DCE-MRI after salvage radiotherapy for prostate cancer.Clinical and translational radiation oncology · 2022Article
- Quantitative Synthetic Magnetic Resonance Imaging for Brain Metastases: A Feasibility Study.Cancers · 2022Article
- Multimodality MRI-based radiomics approach to predict the posttreatment response of lung cancer brain metastases to gamma knife radiosurgery.European radiology · 2022Article
- Brain metastases: the role of clinical imaging.The British journal of radiology · 2022Review
- Clinical Biomarkers for Early Identification of Patients with Intracranial Metastatic Disease.Cancers · 2021Review
- Diffusion and Perfusion MRI Predicts Response Preceding and Shortly After Radiosurgery to Brain Metastases: A Pilot Study.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2021Article
- Magnetic Resonance Imaging Segmentation on the Basis of Boundary Tracking Algorithm in Lung Cancer Surgery.Contrast media & molecular imaging · 2021Article
- Simultaneous Metabolic and Perfusion Imaging Using HyperpolarizedInternational journal of radiation oncology, biology, physics · 2020Article
- Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases.Neuro-oncology · 2020Article
- Deep learning-based detection and segmentation-assisted management of brain metastases.Neuro-oncology · 2020Article
- DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR.Clinical and translational radiation oncology · 2020Article
- Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.Neuro-oncology · 2020Review
- Computational Modeling of Interstitial Fluid Pressure and Velocity in Non-small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery.Frontiers in neurology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Background: Imaging criteria to evaluate the response of brain metastases to stereotactic radiosurgery (SRS) in the early posttreatment period remains a crucial unmet need. The aim of this study is to correlate early (within 12 wk) posttreatment perfusion MRI changes with long-term outcomes after treatment of lung cancer brain metastases with SRS. Methods: Pre- and posttreatment perfusion MRI scans were obtained in patients treated with SRS for intact non-small cell lung cancer brain metastases. Time-dependent leakage (Ktrans), blood plasma volume (Vp), and extracellular extravascular volume (Ve) were calculated for each lesion. Patients were followed longitudinally with serial MRI until death, progression, or intervention (whole brain radiation or surgery). Results: We included 53 lesions treated with SRS from 41 total patients. Median follow-up after treatment was 11 months. Actuarial local control at one year was 85%. Univariate analysis demonstrated a significant difference (P = 0.032) in posttreatment Ktrans SD between patients with progressive disease (mean = 0.0317) and without progressive disease (mean = 0.0219). A posttreatment Ktrans SD cutoff value of 0.017 was highly sensitive (89%) for predicting progressive disease and no progressive disease. Early posttreatment volume change was not associated with outcome (P = 0.941). Conclusion: Posttreatment Ktrans SD may be used as an early posttreatment imaging biomarker to help predict long-term response of lung cancer brain metastases to SRS. This can help identify patients who will ultimately fail SRS and allow for timelier adjustment in treatment approach. These data should be prospectively validated in larger patient cohorts and other histologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.